Both in vivo and in vitro experiments have demonstrated that SP-A and SP-D have protective effects against devastating NEC disease by downregulating Toll-like receptor 4-mediated inflammatory responses and protect mucosal barrier integrity.19,38. Here, TLR4 is linked to necrotizing enterocolitis.